Mimedx Group IncMDXG
Price$4.64Intrinsic value$3.8517% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $355.2M+1.8% YoYTTM through 30 Jun 2026
Net Income $6.2M-85.3% YoYTTM through 30 Jun 2026

Margins

Current
Gross Margin70.6%
EBITDA Margin6.7%
Operating Margin-27.2%
Net Margin1.8%

Returns

12.6%ROE
9.9%ROA
11.8%ROIC

Balance Sheet Health

Debt / Equity0.07x
Current Ratio5.39x
Net Debt-$142.2Mnet cash position
Cash & Equivalents$135.8M

Quality Metrics

Altman Z-Score8.38
Piotroski F-Score5 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $418.6M
Diluted EPS$0.04TTM
'19'20'21'22'23'24'25
FY2025: $0.32

Dividend

No dividend

Capital Allocation

R&D Spend$15.4M
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.